Testing gemcitabine with BCG for returning bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of bladder cancer called non-muscle invasive that has come back after treatment with BCG.
- Your cancer is high grade (more aggressive) and confirmed by biopsy within the last 4 months.
- All visible tumors (except for flat areas called CIS) have been removed by a procedure called TURBT within the last 3 months.
- You have not had severe side effects from BCG or other bladder treatments in the past.
- You have no history of cancer that has spread to the muscle layer or beyond.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
This trial tests a personalized approach to using BCG immunotherapy for high-risk non-muscle-invasive bladder cancer. It aims to improve treatment response by tailoring the therapy based on your immune system.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This study tests a combination of two chemotherapy drugs, mitomycin-C and gemcitabine, given directly into the bladder for people with high-risk bladder cancer that hasn't been controlled with BCG therapy. It's an option for those who can't or don't want to have their bladder removed.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
Hear when a new Recurrent Non-Muscle Invasive Bladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.